GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

QTX-3046 is under development for the treatment of solid tumor, colorectal, pancreatic, endometrial cancer and lung cancer. It is administered through oral route. The drug candidate acts by targeting ...

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL).

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Cystic Fibrosis.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

Anti-PD-1/VEGF BsAb is under clinical development by 3SBio and currently in Phase II for Gynecological Cancer.

R3R-01 is under development for the treatment of Alport syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. It is administered through oral route.

BH-30236 is under clinical development by BlossomHill Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

PrimePro is under clinical development by Thomas Advanced Medical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

PF-07934040 is under clinical development by Pfizer and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase ...

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.